Jane Street Group LLC Has $89,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Jane Street Group LLC cut its stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 75.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,741 shares of the company’s stock after selling 51,005 shares during the period. Jane Street Group LLC’s holdings in Monte Rosa Therapeutics were worth $89,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its holdings in shares of Monte Rosa Therapeutics by 16.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 109,864 shares of the company’s stock worth $411,000 after acquiring an additional 15,845 shares during the period. Acadian Asset Management LLC lifted its stake in Monte Rosa Therapeutics by 77.4% during the second quarter. Acadian Asset Management LLC now owns 98,557 shares of the company’s stock worth $366,000 after purchasing an additional 43,009 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Monte Rosa Therapeutics by 46.0% in the 2nd quarter. American Century Companies Inc. now owns 49,410 shares of the company’s stock valued at $185,000 after purchasing an additional 15,562 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Monte Rosa Therapeutics by 111.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 153,758 shares of the company’s stock valued at $575,000 after purchasing an additional 81,083 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Monte Rosa Therapeutics by 108.6% during the 2nd quarter. Renaissance Technologies LLC now owns 254,714 shares of the company’s stock worth $953,000 after buying an additional 132,614 shares in the last quarter. 79.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, major shareholder Versant Venture Capital Vi, L. sold 89,990 shares of the stock in a transaction on Monday, October 28th. The shares were sold at an average price of $9.66, for a total transaction of $869,303.40. Following the transaction, the insider now owns 2,007,948 shares of the company’s stock, valued at approximately $19,396,777.68. This trade represents a 4.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.50% of the stock is currently owned by insiders.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE opened at $5.56 on Wednesday. The firm has a market capitalization of $341.59 million, a P/E ratio of -3.04 and a beta of 1.47. Monte Rosa Therapeutics, Inc. has a 52 week low of $3.21 and a 52 week high of $12.40. The stock has a 50 day moving average price of $7.98 and a two-hundred day moving average price of $6.29.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, November 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.16. The business had revenue of $9.22 million for the quarter, compared to analysts’ expectations of $4.54 million. On average, equities analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wedbush reissued an “outperform” rating and issued a $15.00 price objective on shares of Monte Rosa Therapeutics in a research note on Thursday, November 7th. Wells Fargo & Company cut Monte Rosa Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $14.00 to $11.00 in a research note on Thursday, December 19th.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.